Researchers in the Department of Pathology and Laboratory Medicine at Indiana University School of Medicine have discovered a novel anti-cancer drug, using a unique approach that has allowed them to target previously undruggable cancerous proteins.
The Indiana University Melvin and Bren Simon Comprehensive Cancer Center has named Antwione Haywood, PhD, its associate director of diversity, equity and inclusion (DEI). Haywood is the first person to hold the chief diversity officer position at the cancer center.
Two Indiana University Melvin and Bren Simon Comprehensive Cancer Center researchers are now part of a prestigious Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute.
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified how restoring a missing molecule in pancreatic fibrosis could help deliver treatments to cancer cells.
INDIANAPOLIS—A researcher at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center received a five-year, $2.5 million grant from the National Cancer Institute to develop a novel therapy to treat lung cancer.
A group of researchers from Indiana University School of Medicine and Indiana University Bloomington have developed a program called Multi-Omics Graph cOnvolutional NETworks (MOGONET) that integrates omics data – such as DNA, RNA and proteins – to help researchers get a comprehensive understanding of human diseases. MOGONET can identify potential biomarkers for Alzheimer’s disease and cancers from the various omics data to predict which individuals may be at higher risk.
Indiana University Melvin and Bren Simon Comprehensive Cancer Center has joined National Cancer Institute (NCI)-designated cancer centers and other organizations in a joint statement urging the nation’s health care systems, physicians, parents and children, and young adults to get the human papillomavirus (HPV) vaccination back on track.
Cancer researchers at Indiana University and the University of Pittsburgh received a five-year, $3 million grant from the National Cancer Institute (NCI) to study cognitive dysfunction after chemotherapy.